Chemical inhibitors of TNFa-IP8 target the protein's function by interfering with the processes and pathways that regulate its activity. Marimastat, as a broad-spectrum matrix metalloprotease (MMP) inhibitor, can inhibit the remodeling of the extracellular matrix, which is essential for the modulation of the cellular environment that TNFa-IP8 is involved in. Similarly, Ilomastat, Batimastat, Prinomastat, Rebimastat, Ro 32-3555, and Ro 28-2653, all of which are MMP inhibitors, can hinder the degradation of extracellular matrix components, thereby indirectly limiting the activity of TNFa-IP8. The MMP inhibition prevents the normal remodeling and breakdown of extracellular matrix, which is crucial for the signaling pathways that TNFa-IP8 may influence. By stabilizing the extracellular matrix, these inhibitors can reduce the matrix-associated signaling that regulates the function of TNFa-IP8.
In addition to MMP inhibitors, other compounds such as TAPI-0 and GW280264X focus on inhibiting tumor necrosis factor alpha converting enzyme (TACE) and the shedding of cell surface molecules facilitated by ADAM10. These enzymes are involved in the processing of cytokines and cell surface molecules that can modulate TNFa-IP8 activity. By inhibiting TACE and ADAM10, GW280264X can decrease the activity of cytokines like TNF alpha, which regulates TNFa-IP8. TAPI-0 shares a similar mechanism, aiming to reduce the functional activity of TNFa-IP8 by decreasing the availability and activity of TNF alpha. KB-R7785 takes a different approach by targeting the renin-angiotensin system, downregulating angiotensin II type 1 receptor signaling, which can influence inflammatory responses and, consequently, the activity of TNFa-IP8. By mitigating these signaling pathways, KB-R7785 can exert an inhibitory effect on TNFa-IP8. These chemical inhibitors collectively work on different fronts to regulate the activity of TNFa-IP8 by targeting the protein's interaction with its surrounding environment and the signaling pathways that contribute to its function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloprotease (MMP) inhibitor that can inhibit TNFa-IP8 function by preventing the extracellular matrix remodeling which TNFa-IP8 is involved in, thus indirectly inhibiting the protein's ability to modulate the cellular environment. | ||||||
GW 280264X | 866924-39-2 | sc-507540 | 5 mg | $720.00 | ||
GW280264X acts similarly to TAPI-0 by inhibiting TACE as well as ADAM10, which are involved in the shedding of cell surface molecules, a process that can influence TNFa-IP8 activity through the regulation of cell signaling pathways. | ||||||
PD166793 | 199850-67-4 | sc-202709 | 5 mg | $150.00 | 6 | |
PD166793 is a synthetic MMP inhibitor that can inhibit the degradation of the extracellular matrix, a process in which TNFa-IP8 may be indirectly involved. By inhibiting MMPs, the remodeling of the extracellular matrix is reduced, which can inhibit the function of TNFa-IP8. | ||||||
Ro 32-3555 | 190648-49-8 | sc-296277 | 10 mg | $413.00 | 2 | |
Ro 32-3555 is an MMP inhibitor that can inhibit collagen breakdown, altering the extracellular environment and potentially reducing the functional activity of TNFa-IP8 by limiting the matrix-associated signaling pathways. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Batimastat is a potent MMP inhibitor that can prevent the breakdown of the extracellular matrix components, which could inhibit the function of TNFa-IP8 by reducing the matrix remodeling associated with cellular signaling. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
Ilomastat, also known as GM6001, is an MMP inhibitor that can impede the extracellular matrix degradation. Since TNFa-IP8 might be involved in matrix-related signaling, the inhibition of MMPs can lead to a functional inhibition of TNFa-IP8. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
Prinomastat is an MMP inhibitor that can affect tumor invasion and metastasis by altering the extracellular matrix. This alteration can inhibit the function of TNFa-IP8 by limiting the extracellular signals required for its activity. | ||||||